Prevest Denpro Ltd

Summary of Certificate under Regulation 74(5)

• No dematerialisation/rematerialisation requests were received during the quarter ended 30 September 2026.
• Regulation 74(5) not applicable as the entire holding is in demat form.

Prevest Denpro Limited: Trading Window closed from October 01, 2026 in connection with unaudited quarterly and half-year results for the period ended September 30, 2026; will reopen 48 hours after the results are declared

AGM Details

• Date and time: 17 Sep 2026, 12:30 IST.
• Mode: Video Conferencing (VC) / OAVM.
• AGM duration: 12:30–14:05.
• Scrutinizer's report dated 19 Sep 2026.

Key Resolutions & Outcomes

• Adoption of audited standalone and consolidated financial statements—passed with majority.
• Final dividend of Rs 1 per share approved.
• Re-appointment of Niharika Modi as Director (retiring by rotation)—passed.
• Appointment of M/s A D V & Associates as statutory auditors—passed.
• Remuneration of cost auditors ratified—passed.
• Namrata Modi re-appointed as Whole-Time Director—Special Resolution—passed.
• Sai Kalyan Surapaneni re-appointed as Executive Director with remuneration—Special—passed.
• Piyush Gupta appointed Independent Director—passed.
• Abhijeet Haridas appointed Independent Director—passed.
• Sukhen Pal Babuta appointed Independent Director—passed.
• Waiver of excess remuneration to Sai Surapaneni—Special—passed.

Director Changes

• Independent Directors regularized: Piyush Gupta, Abhijeet Haridas, Sukhen Pal Babuta.
• Namrata Modi re-appointed as Whole-Time Director.
• Niharika Modi re-appointed as Director (retiring by rotation).
• Sai Kalyan Surapaneni re-appointed as Executive Director.

Auditor Appointments

• Statutory Auditor: M/s A D V & Associates appointed.

Material Related Party Transactions

• Waiver of recovery of excess remuneration to Executive Director approved.

AGM Details

• Date and time: 17 Sep 2026 at 12:30 IST; mode: VC/OAVM.
• Duration: 12:30 p.m. to 2:05 p.m.
• Quorum: 19 members; meeting constituted.
• Remote e-voting window: 14 Sep 2026 9:00 AM to 16 Sep 2026 5:00 PM.
• Registered office deemed venue; live webcast via NSDL.

Resolutions & Status

• Adopt standalone and consolidated financial statements; Ordinary; status: pending.
• Declare final dividend of ₹1 per equity share; Ordinary; status: pending.
• Re-appoint Niharika Modi as Director (retires by rotation); Ordinary; status: pending.
• Appoint M/s A D V & Associates as Statutory Auditors; Ordinary; status: pending.
• Ratify remuneration of Cost Auditors; Ordinary; status: pending.
• Re-appoint Namrata Modi as Whole-Time Director; Special; status: pending.
• Re-appoint Sai Kalyan Surapaneni as Executive Director; Special; status: pending.
• Appoint Piyush Kiranprakash Gupta as Independent Director; Ordinary; status: pending.
• Appoint Abhijeet Sadashiv Haridas as Independent Director; Ordinary; status: pending.
• Appoint Sukhen Pal Babuta as Independent Director; Ordinary; status: pending.
• Waiver of excess managerial remuneration to Sai Kalyan Surapaneni; Special; status: pending.
• Voting results and Scrutinizer’s report to be uploaded after AGM.

AGM notice and access details

• 27th AGM scheduled for Sept 17, 2026 via Video Conferencing.
• Cut-off date for voting eligibility is Sept 10, 2026.
• Electronic voting opens Sept 14, 2026 and ends Sept 16, 2026.
• Shareholders without registered emails received notice via link to AGM and AR.
• Notice and Integrated Annual Report accessible from company site and BSE/NSDL portals.

Financial performance

• Standalone revenue from operations ₹7,666.12 Lakhs, up 13.63% YoY.
• Standalone PAT ₹2,141.82 Lakhs, up 17.67% YoY.
• Consolidated revenue ₹7,672.36 Lakhs, up 13.93% YoY.
• Consolidated PAT ₹2,049.05 Lakhs, up 12.86% YoY.
• EBITDA up 16.65%; PBT up 17.58%; PAT up 17.67% YoY.
• UAE subsidiary established as part of international expansion.
• Final dividend of ₹1 per equity share proposed.
• Paid-up capital ₹12.003 crore; no new shares issued.
• Balance sheet remains debt-free.

Growth & strategic initiatives

• Overseas expansion: UAE subsidiary established; Axiodent Inc. in USA; Gulf General Trading LLC.
• Disinfectants business commercialized; new growth vertical.
• Digital dentistry portfolio expanded with next-gen 3D printing solutions.
• Rotoflex endodontic file system strengthened with strong market response.
• Global footprint expanded to 90+ countries; three overseas subsidiaries.
• MoU with IIT Kanpur for biomaterials; Prevest Research Institute recognized as DSIR center.
• EPIP plant capacity >200 MT/year; in-house raw-material synthesis.
• R&D: 20+ collaborations with dental colleges; focus on biomaterials and digital tech.
• Approximately 16 educational/clinical training programs conducted.

Governance & controls

• Board size six with two women; several KMP changes in 2025-26.
• Independent Directors declared independence; data bank maintained with IICA.
• Audit Committee reconstituted on 22-Apr-2026; NRC and other panels reconstituted.
• Statutory auditors appointed: A D V & Associates; prior: Mittal & Associates.
• Secretarial auditor: NKM & Associates; Internal auditor: VNB & Co; Cost auditor: PAN & Associates.
• Governance gaps noted: Reg 30 intimation lapses; ED remuneration excess; tenure intimation delays.
• Seven board meetings held in 2025-26; attendance details recorded.
• Independents comply with applicable codes; no director disqualification.

Dividends & capital management

• Final dividend of ₹1 per equity share; subject to shareholder approval.
• No transfer to general reserve during the year.
• Paid-up capital ₹12.003 crore; no new shares issued.
• SME listing on BSE; annual listing fees for 2025-26 paid.

CSR & sustainability

• CSR spend totaled ₹42.11 Lakhs; 2% average net profit obligation ₹44.43 Lakhs.
• Average net profit (last 3 years) ₹22.21 Crores.
• Projects cover education, healthcare, skill development, hunger relief, floods relief, plantation.
• Key initiatives include government school upgrades, Prevest Spark scholarships, apprenticeships.
• Administrative CSR overhead ₹0.72 Lakhs; openings balances tracked; website disclosures.
• CSR policy, projects and impact disclosures published on company website.
• Opening CSR balance negative; closing balance as of year end ₹-1.25 Lakhs.
• CSR expenditure aligned with Schedule VII; ongoing and non-ongoing projects disclosed.

Subsidiaries & consolidation

• Wholly owned subsidiaries: Denvisio Biomed Limited, Axiodent Inc., Prevest Denpro Gulf General Trading LLC.
• US and India subsidiaries fully owned; Dubai entity yet to commence operations.
• Consolidated results include all active subsidiaries; Dubai subsidiary shown with 0% holding.
• Annexure AOC-1 provides salient features of subsidiaries.

Outlook & risk

• Positive outlook driven by digital dentistry and disinfectants growth.
• Domestic expansion to Tier II/III markets; broader export footprint.
• Invest in digital workflows, 3D printing, and integrated restorative solutions.
• Continue localization and indigenous raw material initiatives to reduce import reliance.

AGM Details

• Date/time: 17 Sep 2026, 12:30 PM IST via VC/OAVM.
• Mode: VC/OAVM; deemed venue: registered office.
• Record date: 10 Sep 2026; remote e-voting: 14–16 Sep 2026.
• NSDL e-voting facility for remote voting.

Dividend

• Final dividend of ₹1 per equity share approved.

Ordinary Resolutions

• Adopt standalone and consolidated financial statements for FY 2025-26.
• Re-appoint Niharika Modi as Director by rotation.
• Appoint M/s ADV & Associates as Statutory Auditors for five years.

Special Resolutions

• Remuneration ratified for Pan & Associates Cost Auditor: ₹1 Lakh per year.
• Namrata Modi re-appointed Whole Time Director for 3 years.
• Remuneration up to ₹15 Lakh per month for Namrata Modi.
• Sai Kalyan Surapaneni re-appointed Executive Director for 3 years.
• Remuneration up to ₹70 Lakh per annum.
• Piyush Gupta appointed Independent Director for 5 years.
• Abhijeet Haridas appointed Independent Director for 5 years.
• Sukhen Pal Babuta appointed Independent Director for 5 years.
• Waiver of excess remuneration recovery for Sai Kalyan Surapaneni (2024-25, 2025-26).

Auditors

• Statutory auditors appointed for five-year term.
• Remuneration for 2026-27 proposed at ₹7.2 Lakh; subsequent years to be fixed by the Board.

Related Party Transactions

• Waiver of excess remuneration recovery constitutes related party transaction.

Director Changes

• Namrata Modi: Whole Time Director appointment for 3 years.
• Sai Kalyan Surapaneni: Executive Director appointment for 3 years.
• New Independent Directors: Gupta, Haridas, Babuta appointed for 5-year terms.

Standalone highlights

• Revenue from operations: ₹1,944.33 lakh, up 23.66% YoY; QoQ ₹1,890.40 lakh (+2.85%).

Standalone totals and profitability

• Total income: ₹2,077.40 lakh, up 22.96% YoY; QoQ ₹2,036.66 lakh (+2.00%).
• EBITDA: ₹821.88 lakh, up 22.60% YoY.
• PBT: ₹770.26 lakh, up 23.96% YoY.
• PAT: ₹578.23 lakh, up 24.77% YoY.

Consolidated highlights

• Revenue from operations: ₹1,906.83 lakh, up 20.94% YoY; QoQ ₹1,894.06 lakh (+0.67%).
• Total income: ₹2,038.36 lakh, up 20.38% YoY; QoQ ₹2,034.67 lakh (+0.18%).
• EBITDA: ₹808.14 lakh, up 24.73% YoY.
• PBT: ₹755.89 lakh, up 26.23% YoY.
• PAT: ₹563.86 lakh, up 27.99% YoY.

Dividend declaration

• Dividend declared: 10% (₹1 per equity share) for FY 2025-26, subject to shareholder approval.

Management commentary

• Management notes strong start to FY2026-27 with double-digit growth across key metrics.
• Consolidated results show revenue growth of 20.94% YoY and double-digit gains in EBITDA, PBT, PAT.
• Outlook remains optimistic with expansion plans domestically and internationally.